Advertisement
MAYAGUEZ, Puerto Rico and BALTIMORE, March 5, 2019 /PRNewswire/ -- CDI Laboratories, Inc. has announced that ~2,000 new recombinant proteins have been added to HuProt™ - its human proteome microarray. This addition now means that CDI's HuProt v4.0 array "v4.0 now contains over 21,000 human proteins and protein isoforms, including >81% of canonically expressed proteins as defined by the Human Protein Atlas." CDI's HuProt™ array is available as a stand-alone product or as part of CDI's services platform. The addition of this additional content further strengthens CDI's position as a global leader in microarray production, content and application development.
HuProt™ microarrays can generate massive binding profiles in days - not months - and are used in:
HuProt microarrays are available for purchase by labs with in-house microarray scanning capability. Alternatively, CDI's Discovery Services division offers contract assay design, research, bioinformatics and custom-configured microarray production on a per-project basis.
About CDI - A privately-owned biotechnology corporation, CDI focuses on protein- and antibody microarray design, production and custom assay services. CDI's flagship - HuProt™ - is the most comprehensive human proteome microarray in the industry, allowing thousands of protein interactions to be done in parallel. HuProt enables R&D of future therapeutic and diagnostic tools to proceed more rapidly and cost-effectively. CDI's Fast-MAb® hybridoma development service addresses the urgent need for monoclonal antibodies with unprecedented specificity for research, diagnostic or therapeutic targets. Fast-MAb antibodies are evaluated for specificity on the HuProt array. The Company exports products world-wide and is expanding its clientele base and its academic and industrial collaborations.
For more information, visit cdi-lab.com
Media Contact:Scott Paschke, VP MarketingCDI Laboratories Inc518-534-2881 (direct)[email protected]
Advertisement
HuProt™ microarrays can generate massive binding profiles in days - not months - and are used in:
- Serum (biomarker) profiling- disease diagnosis, prognosis; cancer immunotherapy, vaccine development
- Protein binding assays- small molecule binding, DNA/RNA binding, enzyme binding specificity, etc.
- Antibody specificity testing- assess cross-reactivity, identify highest quality research reagents
HuProt microarrays are available for purchase by labs with in-house microarray scanning capability. Alternatively, CDI's Discovery Services division offers contract assay design, research, bioinformatics and custom-configured microarray production on a per-project basis.
About CDI - A privately-owned biotechnology corporation, CDI focuses on protein- and antibody microarray design, production and custom assay services. CDI's flagship - HuProt™ - is the most comprehensive human proteome microarray in the industry, allowing thousands of protein interactions to be done in parallel. HuProt enables R&D of future therapeutic and diagnostic tools to proceed more rapidly and cost-effectively. CDI's Fast-MAb® hybridoma development service addresses the urgent need for monoclonal antibodies with unprecedented specificity for research, diagnostic or therapeutic targets. Fast-MAb antibodies are evaluated for specificity on the HuProt array. The Company exports products world-wide and is expanding its clientele base and its academic and industrial collaborations.
For more information, visit cdi-lab.com
Media Contact:Scott Paschke, VP MarketingCDI Laboratories Inc518-534-2881 (direct)[email protected]
View original content:http://www.prnewswire.com/news-releases/cdi-labs-releases-huprot-v4-0---adding-additional-content-to-largest-content-human-proteome-microarray-in-the-world-300806507.html
SOURCE CDI Laboratories
